PT3737423T - Composições e métodos para tratamento de distúrbios da retina - Google Patents

Composições e métodos para tratamento de distúrbios da retina

Info

Publication number
PT3737423T
PT3737423T PT197010184T PT19701018T PT3737423T PT 3737423 T PT3737423 T PT 3737423T PT 197010184 T PT197010184 T PT 197010184T PT 19701018 T PT19701018 T PT 19701018T PT 3737423 T PT3737423 T PT 3737423T
Authority
PT
Portugal
Prior art keywords
compositions
methods
retinal disorders
treating retinal
treating
Prior art date
Application number
PT197010184T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of PT3737423T publication Critical patent/PT3737423T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT197010184T 2018-01-12 2019-01-14 Composições e métodos para tratamento de distúrbios da retina PT3737423T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment

Publications (1)

Publication Number Publication Date
PT3737423T true PT3737423T (pt) 2024-10-03

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197010184T PT3737423T (pt) 2018-01-12 2019-01-14 Composições e métodos para tratamento de distúrbios da retina

Country Status (26)

Country Link
US (2) US11680276B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737423B1 (cg-RX-API-DMAC7.html)
JP (1) JP7289306B2 (cg-RX-API-DMAC7.html)
KR (1) KR102786552B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936172A (cg-RX-API-DMAC7.html)
AU (1) AU2019206314B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014191A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088079A1 (cg-RX-API-DMAC7.html)
DK (1) DK3737423T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091655A1 (cg-RX-API-DMAC7.html)
ES (1) ES2988499T3 (cg-RX-API-DMAC7.html)
FI (1) FI3737423T3 (cg-RX-API-DMAC7.html)
GB (1) GB201800546D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20241483T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068987T2 (cg-RX-API-DMAC7.html)
IL (1) IL275985A (cg-RX-API-DMAC7.html)
LT (1) LT3737423T (cg-RX-API-DMAC7.html)
MX (1) MX2020007366A (cg-RX-API-DMAC7.html)
PH (1) PH12020551071A1 (cg-RX-API-DMAC7.html)
PL (1) PL3737423T3 (cg-RX-API-DMAC7.html)
PT (1) PT3737423T (cg-RX-API-DMAC7.html)
RS (1) RS66227B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006618PA (cg-RX-API-DMAC7.html)
SI (1) SI3737423T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400410T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019138250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
WO2022246089A1 (en) * 2021-05-20 2022-11-24 Artema Therapeutics, Inc. Kcnv2 variants and their use
CA3225080A1 (en) * 2021-07-14 2023-01-19 Anastasios GEORGIADIS Kcnv2 gene therapy
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy
WO2026150224A1 (en) 2024-12-30 2026-07-16 MeiraGTx Ocular UK Limited Modified adeno-associated virus (aav) viral capsid proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CN103608455B (zh) * 2011-01-07 2019-01-15 应用遗传科技公司 用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
FI3265178T3 (fi) * 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Also Published As

Publication number Publication date
SI3737423T1 (sl) 2025-03-31
FI3737423T3 (fi) 2024-11-02
DK3737423T3 (da) 2024-10-21
PH12020551071A1 (en) 2021-09-06
ES2988499T3 (es) 2024-11-20
US20200392536A1 (en) 2020-12-17
EP3737423A1 (en) 2020-11-18
US11680276B2 (en) 2023-06-20
EA202091655A1 (ru) 2020-11-20
GB201800546D0 (en) 2018-02-28
SMT202400410T1 (it) 2025-01-14
CN111936172A (zh) 2020-11-13
US12467066B2 (en) 2025-11-11
SG11202006618PA (en) 2020-08-28
KR20200141435A (ko) 2020-12-18
MX2020007366A (es) 2020-09-03
AU2019206314B2 (en) 2025-02-13
PL3737423T3 (pl) 2025-01-27
CA3088079A1 (en) 2019-07-18
IL275985A (en) 2020-08-31
HRP20241483T1 (hr) 2025-01-03
WO2019138250A1 (en) 2019-07-18
HUE068987T2 (hu) 2025-02-28
AU2019206314A1 (en) 2020-08-13
JP2021510301A (ja) 2021-04-22
NZ766316A (en) 2024-05-31
RS66227B1 (sr) 2024-12-31
EP3737423B1 (en) 2024-09-18
US20240067989A1 (en) 2024-02-29
JP7289306B2 (ja) 2023-06-09
BR112020014191A2 (pt) 2022-02-22
LT3737423T (lt) 2024-11-25
KR102786552B1 (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL275506A (en) Preparations and methods for the treatment of central nervous system disorders
IL275562A (en) Preparations and methods for the treatment of central nervous system disorders
IL275985A (en) Preparations and methods for the treatment of retinal disorders
IL269174B2 (en) Methods of treating inter-mediating diseases or disorders
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
SG11202011151VA (en) Compositions and methods for reducing spliceopathy and treating rna dominance disorders
ZA202002991B (en) Methods and compositions for assessing and treating intraocular diseases and disorders
ZA202104737B (en) Methods and compositions for treating skin and hair disorders
IL270114B1 (en) Methods and compounds for the treatment of neurological diseases
ZA202101362B (en) Compositions and methods for treating the eye
SG11202104053TA (en) Compositions and methods for the treatment of estrogen-dependent disorders
ZA202101342B (en) Compositions and methods for treating the eye
EP3310353A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
IL287831A (en) Oxymetazoline compounds and methods for treating eye diseases
IL287594A (en) Compositions and methods for the treatment of retinal degeneration
EP3634438A4 (en) COMPOSITIONS FOR THE TREATMENT OF NETWORK DISEASES AND METHOD FOR THEIR MANUFACTURE AND USE
EP3737355A4 (en) COMPOSITIONS AND METHODS OF TREATING A NERVE INJURY
ZA202101360B (en) Compositions and methods for treating the eye
ZA202007183B (en) Compositions and methods for treating the eye
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
EP3761988A4 (en) Compositions and methods for treating hyperproliferative skin disorders
IL286571A (en) Compounds and methods for the treatment of neurodegenerative disorders
ZA202101361B (en) Compositions and methods for treating the eye
PT3519050T (pt) Composições para o tratamento de condições oftálmicas